Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
暂无分享,去创建一个
M. Pfeffer | P. Ridker | E. Braunwald | F. Sacks | N. Rifai | E. Braunwald | G. Flaker | L. Moyé | S. Goldman | L. Moye
[1] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[2] J. Sipe,et al. Analytical Evaluation of Particle-Enhanced Immunonephelometric Assays for C-Reactive Protein, Serum Amyloid a and Mannose-Binding Protein in Human Serum , 1998, Annals of clinical biochemistry.
[3] R J Glynn,et al. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.
[4] P. Ridker. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? , 1998, Circulation.
[5] P. Ridker,et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.
[6] L H Kuller,et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[7] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[8] D. Green,et al. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.
[9] S. Thompson,et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.
[10] K. Silver,et al. β3-adrenoceptor gene variant in obesity and insulin resistance , 1996, The Lancet.
[11] Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin , 1996, The Lancet.
[12] B. Buckley,et al. Statins do more than just lower cholesterol , 1996, The Lancet.
[13] L. Kuller,et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.
[14] Y. Shimada,et al. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. , 1996, Immunopharmacology.
[15] E. Donetti,et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1996, Cardiology.
[16] David J. Weatherall,et al. Oxford textbook of medicine , 1996 .
[17] N. Hosomi,et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. , 1996, Atherosclerosis.
[18] I. Sartori. Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris , 1996 .
[19] D. Waters,et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.
[20] G. Rogler,et al. Effects of flwastatin on growth of porcine and human vascular smooth muscle cells in vitro , 1995 .
[21] P. Libby. Molecular bases of the acute coronary syndromes. , 1995, Circulation.
[22] L. Howes,et al. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. , 1995, The American journal of cardiology.
[23] S. Thompson,et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.
[24] M. Casl,et al. Serum Amyloid a Protein in Patients with Acute Myocardial Infarction , 1995, Annals of clinical biochemistry.
[25] A. Yeung,et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.
[26] W. Weintraub,et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.
[27] G. Rogler,et al. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. , 1995, The American journal of cardiology.
[28] M. Aviram,et al. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. , 1994, British journal of clinical pharmacology.
[29] P. Sever,et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis , 1994, European journal of clinical investigation.
[30] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[31] M. Sugimachi,et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.
[32] Koji Suzuki,et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia , 1993, American journal of hematology.
[33] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[34] M. Pfeffer,et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) , 1991, The American journal of cardiology.
[35] W. Weintraub,et al. Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.
[36] A. Maseri,et al. C-Reactive Protein in Myocardial Infarction and Ischaemia , 1982 .